Deutsche Bank initiates coverage of biopharma stocks, sees ’modest recovery’

Published 11/02/2025, 15:52
© Reuters.

Investing.com -- Deutsche Bank initiated coverage on 11 U.S. biopharma stocks in a note Tuesday, assigning Buy ratings to eight companies and Hold ratings to three. 

The bank sees potential for a modest biotech recovery in 2025 following years of underperformance relative to broader market indices but warns of near-term macro volatility tied to the U.S. political environment.

“Our coverage universe focuses on small- and mid-cap biotechnology stocks (and selected large caps) in the central nervous system (CNS) therapeutic area,” Deutsche Bank (ETR:DBKGn) analysts wrote. 

The firm expects continued investor and strategic interest in CNS, particularly in neuropsychiatry, epilepsy, and sleep-wake disorders, which have seen increasing capital markets activity over the past year.

Among the companies covered, Deutsche Bank’s top picks for 2025 are Axsome Therapeutics (NASDAQ:AXSM) and Xenon Pharmaceuticals (NASDAQ:XENE), both rated Buy, with price targets of $176 and $67, respectively. 

“Our Top Picks for 2025 are AXSM and XENE, based on our highest conviction around major near-term catalysts, estimated total return over the next 12 months, and overall their risk/reward profiles,” the analysts wrote.

ALKS, AVDL, BHVN, DNLI, HRMY, and PRAX, were also rated at Buy.

Conversely, Neurocrine (NASDAQ:NBIX) Biosciences and Sarepta Therapeutics (NASDAQ:SRPT) received Hold ratings with price targets of $138 and $136, respectively, and were labeled as the firm’s least preferred names.

Deutsche Bank maintains a cautiously optimistic outlook on the sector, emphasizing that CNS remains one of the most attractive areas for drug development and investment. 

However, the bank’s analysts caution that broader market conditions and macroeconomic uncertainties could impact performance in the near term.

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.